To the Editor We read with great interest the impressive article by Kazandjian and colleagues,1 which demonstrated an association of the lung immune prognostic index (LIPI) score (derived from the neutrophil to lymphocyte ratio [NLR] and the lactate dehydrogenase [LDH] level) with overall survival and progression-free survival among patients with metastatic non–small cell lung cancer (NSCLC) receiving immune checkpoint inhibitors, targeted therapy, or cytotoxic chemotherapy. However, we propose the following 3 points, which should be emphasized in future clinical practice.
Identify all potential conflicts of interest that might be relevant to your comment.
Conflicts of interest comprise financial interests, activities, and relationships within the past 3 years including but not limited to employment, affiliation, grants or funding, consultancies, honoraria or payment, speaker's bureaus, stock ownership or options, expert testimony, royalties, donation of medical equipment, or patents planned, pending, or issued.
Err on the side of full disclosure.
If you have no conflicts of interest, check "No potential conflicts of interest" in the box below. The information will be posted with your response.
Not all submitted comments are published. Please see our commenting policy for details.
Long J, Lin J, Zhao H. Application of the Lung Immune Prognostic Index From Research to Clinical Practice. JAMA Oncol. Published online November 27, 2019. doi:https://doi.org/10.1001/jamaoncol.2019.5151
Browse and subscribe to JAMA Network podcasts!
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: